Cutaneous Vasculitis Update 2005:

Review article text

References

1. Stone JH, Nousari HC.‘‘Essential’’ cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin. Curr Opin Rheumatol. 2001;13:23–34.
2. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48: 311–340.
3. Langford CA.15. Vasculitis. J Allergy Clin Immunol. 2003;111(Suppl 2): S602–S612.
4. Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol. 03;30:161–173.
5. Jennette CJ, Milling DM, Falk RJ. Vasculitis affecting the skin. A review. Arch Dermatol 1994;130:899–906.
6. McLaren JS, McRorie ER, Luqmani RA. Diagnosis and assessment of systemic vasculitis. Clin Exp Rheumatol. 2002;20:854–862.
7. Weedon D. The vasculopathic reaction pattern. In: Weedon D, ed. Skin Pathology. 2nd ed. Edinburgh: Churchill-Livingstone; 2002:221–280.
8. Sorensen SF, Slot O, Tvede N, et al. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis. 2000;59:478–482.
9. Guillevin L, Lhote F, Amouroux J, et al. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–964.
10. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 004;6:203–211.
11. Wiik A. Autoantibodies in vasculitis. Arthritis Res Ther. 2003;5:147– 152.
12. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000; 43:2025–2033.
13. Sais G, Vidaller A, Jucgla A, et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134:309–315.

14. Jennette JC, Falk RJ. Do vasculitis categorization systems really matter? Curr Rheumatol Rep. 2000;2:430–438.
15. Watts RA, Scott DG. Classification and epidemiology of the vasculitides Baillieres Clin Rheumatol. 1997;11:191–217.
16. Watts RA, Scott DG. Secondary vasculitis. In: Belch J, Zurier R, eds. Conn Tiss Dis. London: Chapman & Hall; 1995:219–247.
17. Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol. 1952; 22:777–790.
18. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33:1135–1136.
19. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33:1101–1107.
20. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;
33:1094–1100.
21. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–1128.
22. Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch- Schonlein purpura. Arthritis Rheum. 1990;33:1114–1121.
23. Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum. 1990;33:1108–1113.
24. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33:1088–1093.
25. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–1134.
26. Callen JP. Cutaneous vasculitis: what have we learned in the past 20 years? Arch Dermatol. 1998;134:355–357.
27. Bloch DA, Michel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum. 1990;33:1068–1073.
28. Bloch DA, Moses LE, Michel BA. Statistical approaches to classification. Methods for developing classification and other criteria rules. Arthritis Rheum. 1990;33:1137–1144.
29. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129:345–352.
30. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–192.
31. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 1990;33:1065–1067.
32. Lotti T, Ghersetich I, Comacchi C, et al. Cutaneous small-vessel vasculitis. J Am Acad Dermatol. 1998;39:667–687; quiz 688-90.
33. Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, et al. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997;102:186–191.
34. Watts RA, Jolliffe VA, Carruthers DM, et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum. 1996;39:1208–1212.
35. Bruce IN, Bell AL. A comparison of two nomenclature systems for primary systemic vasculitis. Br J Rheumatol. 1997;36:453–458.
36. Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97–111.
37. Ioannidou DJ, Krasagakis K, Daphnis EK, et al. Cutaneous small vessel vasculitis: an entity with frequent renal involvement. Arch Dermatol. 2002;138:412–414.
38. Jones R. Criteria for identifying vasculitis of small blood vessels by conventional microscopy. Am J Dermatopathol. 1985;7:181–187.
39. LeBoit PE. Vasculitis: the true and the near-true. Am J Dermatopathol 2002;24:267–269.
40. Bajema IM, Bruijn JA. What stuff is this! A historical perspective on fibrinoid necrosis. J Pathol. 2000;191:235–238.

41. Ruiter M. Vascular fibrinoid in cutaneous ‘‘allergic’’ arteriolitis. J Invest Dermatol. 1962;38:85–92.
42. Akosa AB, Lampert IA. The sweat gland in cutaneous vasculitis. Histopathology. 1991;18:553–558.
43. Cid MC, Segarra M, Garcia-Martinez A, et al. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep. 2004;6:184–194.
44. LeBoit PE, Yen TS, Wintroub B. The evolution of lesions in erythema elevatum diutinum. Am J Dermatopathol. 1986;8:392–402.
45. McMenamin ME, Fletcher CD. Reactive angioendotheliomatosis: a study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol. 2002;26:685–697.
46. Mimouni D, Ng PP, Rencic A, et al. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol. 2003;148:789–794.
47. Zelger B, Sepp N, Schmid KW, et al. Life history of cutaneous vascular lesions in Sneddon’s syndrome. Hum Pathol. 1992;23:668–675.
48. Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol. 2002;138:345–349.
49. Cohen PR. Skin lesions of Sweet syndrome and its dorsal hand variant contain vasculitis: an oxymoron or an epiphenomenon? Arch Dermatol. 2002;138:400–403.
50. Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130:1278–1283.
51. Wilmoth GJ, Perniciaro C. Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease. J Am Acad Dermatol. 1996;34:753–759.
52. Dicken CH,Winkelmann RK. The Churg-Strauss granuloma: cutaneous, necrotizing, palisading granuloma in vasculitis syndromes. Arch Pathol Lab Med. 1978;102:576–580.
53. Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore). 1983;62:142–158.
54. Magro CM, Crowson AN. The cutaneous neutrophilic vascular injury syndromes: a review. Semin Diagn Pathol. 2001;18:47–58.
55. Lynch JM, Barrett TL. Collagenolytic (necrobiotic) granulomas: part II— the "red" granulomas. J Cutan Pathol. 2004;31:409–418.
56. Lynch JM, Barrett TL. Collagenolytic (necrobiotic) granulomas: part 1— the ‘‘blue’’ granulomas. J Cutan Pathol. 2004;31:353–361.
57. Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology. 2001;202:123– 126.
58. McCalmont T, Kuo T, Scott G, et al. Lymphocytic vasculitis in lupus panniculitis: an overlooked mechanism of pathogenetic importance? J Cutan Pathol. 1995;22:73.
59. Crowson AN, Magro CM. Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases. Hum Pathol. 1997;28:478–484.
60. Calamia KT, Balabanova M. Vasculitis in systemic lupus erythematosus. Clin Dermatol 2004;22:148–156.
61. Carlson JA, Mihm MC Jr, LeBoit PE. Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Semin Diagn Pathol. 1996;13:72–90.
62. Carlson JA, LeBoit PE. Localized chronic fibrosing vasculitis of the skin: an inflammatory reaction that occurs in settings other than erythema elevatum diutinum and granuloma faciale. Am J Surg Pathol.
1997;21:698–705.
63. Magro CM, Crowson AN. A clinical and histologic study of 37 cases of immunoglobulin A- associated vasculitis. Am J Dermatopathol. 1999; 21:234–240.
64. Gibson LE. Cutaneous vasculitis update. Dermatol Clin. 2001;19:603– 615.
65. Jessop SJ. Cutaneous leucocytoclastic vasculitis: a clinical and aetiological study. Br J Rheumatol. 1995;34:942–945.
66. Garcia-Porrua C, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch- Schonlein purpura in adults. Semin Arthritis Rheum. 1999;28:404–412.
67. Sanchez NP, Van Hale HM, Su WP. Clinical and histopathologic spectrum of necrotizing vasculitis. Report of findings in 101 cases. Arch Dermatol. 1985;121:220–224.

68. Ekenstam E, Callen JP. Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984;120:484–489.
69. Hodge SJ, Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol. 1987;14:279–284.
70. Gyselbrecht L, De Keyser F, Ongenae K, et al. Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol. 1996;14:665–668.
71. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore). 1998;77:403–418.
72. McCombs RP. Systemic ‘‘allergic’’ vasculitis. Clinical and pathological relationships. JAMA. 1965;194:1059–1064.
73. Winkelmann RK, Ditto WB. Cutaneous and visceral syndromes of necrotizing or ‘‘allergic’’ angiitis: a study of 38 cases. Medicine (Baltimore). 1964;43:59–89.
74. Mackel SE, Jordon RE. Leukocytoclastic vasculitis. A cutaneous expression of immune complex disease. Arch Dermatol. 1982;118:296– 301.
75. Handel DW, Roenigk HH Jr, Shainoff J, et al. Necrotizing vasculitis. Etiologic aspects of immunology and coagulopathy. Arch Dermatol. 1975;111:847–852.
76. San Jose A, Bosch JA, Knobel H, et al. [Hypersensitivity vasculitis. A study of 106 cases.] Rev Clin Esp. 1986;178:368–372.
77. Chua SH, Lim JT, Ang CB. Cutaneous vasculitis seen at a skin referral centre in Singapore. Singapore Med J. 1999;40:147–150.
78. Miquel-Collell C, Rubies-Prat J, Caralps A, et al. [Necrotizing angiitis of small vessels. A clinical study of 25 patients with skin biopsy.] Med Clin (Barc). 1979;72:139–144.
79. Watts RA, Jolliffe VA, Grattan CE, et al. Cutaneous vasculitis in a defined population—clinical and epidemiological associations. J Rheumatol. 1998;25:920–924.
80. Cribier B, Couilliet D, Meyer P, et al. The severity of histopathological changes of leukocytoclastic vasculitis is not predictive of extracutaneous involvement. Am J Dermatopathol. 1999;21:532–536.
81. Barnadas MA, Perez E, Gich I, et al. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol. 2004;43:19–26.
82. Soter NA, Mihm MC Jr, Gigli I, et al. Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol. 1976;66:344–350.
83. Winkelmann RK. The spectrum of cutaneous vasculitis. Clin Rheum Dis. 1980;6:413–452.
84. Panuphak P, Kohler P. Recent advances in allergic vasculitis. Adv Asthma Allergy Pulm Dis 1978;5(2):1928.
85. Grunwald MH, Avinoach I, Amichai B, et al. Leukocytoclastic vasculitis–correlation between different histologic stages and direct immunofluorescence results. Int J Dermatol. 1997;36:349–352.
86. Dauchel H, Joly P, Delpech A, et al. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Clin Exp Immunol. 1993;92:274–283.
87. Schroeter AL, Copeman PW, Jordon RE, et al. Immunofluorescence of cutaneous vasculitis associated with systemic disease. Arch Dermatol. 1971;104:254–259.
88. Boom BW, Out-Luiting CJ, Baldwin WM, et al. Membrane attack complex of complement in leukocytoclastic vasculitis of the skin. Presence and possible pathogenetic role. Arch Dermatol. 1987;123:
1192–1195.
89. Chuaqui R, Gonzalez S. Cutaneous angiitis: direct immunofluorescence and morphopathology in 23 cases. Rev Med Chil. 1989;116:520–524.
90. Kulthanan K, Pinkaew S, Jiamton S, et al. Cutaneous leukocytoclastic vasculitis: the yield of direct immunofluorescence study. J Med Assoc Thai. 2004;87:531–535.
91. Dolezalova P, Telekesova P, Nemcova D, et al. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol. 2004;31:2295–2299.
92. Watts RA, Scott DG. Epidemiology of the vasculitides. Curr Opin Rheumatol. 2003;15:11–16.
93. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am. 2001;27:729–749.

94. Lane SE, Watts RA, Bentham G, et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 2003;48:814–823.
95. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis,Wegener’s granulomatosis, and Churg- Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92–99.
96. Liu NH, LaBree LD, Feldon SE, et al. The epidemiology of giant cell arteritis: a 12-year retrospective study. Ophthalmology. 2001;108:1145–1149.
97. Amoli MM, Thomson W, Hajeer AH, et al. HLA-DRB1*01 association with Henoch-Schonlein purpura in patients from northwest Spain. J Rheumatol. 2001;28:1266–1270.
98. Amoli MM, Mattey DL, Calvino MC, et al. Polymorphism at codon 469 of the intercellular adhesion molecule-1 locus is associated with protection against severe gastrointestinal complications in Henoch-
Schonlein purpura. J Rheumatol. 2001;28:1014–1018.
99. Liu Z, Yang J, Chen Z, et al. Gene polymorphism in IL-1 receptor antagonist affects its production by monocytes in IgA nephropathy and Henoch-Schonlein nephritis. Chin Med J (Engl). 2001;114:1313– 1316.
100. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.
101. Ratnam KV, Boon YH, Pang BK. Idiopathic hypersensitivity vasculitis: clinicopathologic correlation of 61 cases. Int J Dermatol. 1995;34:786–789.
102. Juvonen T, Juvonen J, Savolainen MJ. Is vasculitis a significant component of atherosclerosis? Curr Opin Rheumatol. 1999;11:3–10.
103. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78:292–308.
104. Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998;17:364–368.
105. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis
Rheum. 2003;49(3):388–393.
106. Watts RA, Mooney J, Lane SE, et al. Rheumatoid vasculitis: becoming extinct? Rheumatology (Oxford) 2004;43:920–923.
107. Weck KE, Dal Canto AJ, Gould JD, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus- induced vascular disease. Nat Med. 1997;3:1346–1353.
108. Ryan T. Cutaneous vasculitis. In: Champion R, Burton J, Burns D, Breathnach SM, eds. Textbook of Dermatology. 6th ed. Oxford: Blackwell Scientific Publications; 1998:2155–2225.
109. Mekkes JR, Loots MA, van der Wal AC, et al. Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol. 2004;50:104–107.
110. Claudy A. Coagulation and fibrinolysis in cutaneous vasculitis. Clin Dermatol. 1999;17:615–618.
111. Green ST, Natarajan S. The Koebner phenomenon in anaphylactoid purpura. Cutis. 1986;38:56–57.
112. Inaloz HS, Evereklioglu C, Unal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcet’s syndrome. J Eur Acad Dermatol Venereol. 2004;18:56–61.
113. Harper L, Williams JM, Savage CO. The importance of resolution of inflammation in the pathogenesis of ANCA-associated vasculitis. Biochem Soc Trans. 2004;32:502–506.
114. Bacon PA. The spectrum of Wegener’s granulomatosis and disease relapse. N Engl J Med. 2005;352:330–332.
115. Jennette JC. Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis. Cleve Clin J Med. 2002;69 (Suppl 2):SII33–SII38.
116. Romagnoli P, Ghersetich I, Lotti T. Langerhans cells and vasculitis. Int Angiol. 1995;14:113–118.
117. Wagner AD, Wittkop U, Prahst A, et al. Dendritic cells co-localize with activated CD4+ T cells in giant cell arteritis. Clin Exp Rheumatol. 2003; 21:185–192.
118. Buckley CD, Ed Rainger G, Nash GB, et al. Endothelial cells, fibroblasts and vasculitis. Rheumatology (Oxford) 2005:44:860–863.

119. Filer AD, Gardner-Medwin JM, Thambyrajah J, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis. 2003;62:162–167.
120. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol. 2005; 17:49–55.
121. Booth AD, Wallace S, McEniery CM, et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum. 2004;50:581–588.
122. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718–1723.
123. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibodyassociated systemic vasculitis. J Am Soc Nephrol. 2004;15:717–721.
124. De Leeuw K, Sanders JS, Stegeman CA, et al. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann Rheum Dis. 2004;64:753–759.
125. Morbini P, Dal Bello B, Arbustini E. Coronary artery inflammation and thrombosis in Wegener’s granulomatosis-polyarteritis nodosa overlap syndrome. G Ital Cardiol. 1998;28:377–382.
126. Sunderkotter C, Seeliger S, Schonlau F, et al. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol. 2001;10: 391–404.
127. Haas M, Kraus ES, Samaniego-Picota M, et al. Acute renal allograft rejection with intimal arteritis: histologic predictors of response to therapy and graft survival. Kidney Int. 2002;61:1516–1526.
128. Mihatsch MJ, Nickeleit V, Gudat F. Morphologic criteria of chronic renal allograft rejection. Transplant Proc. 1999;31:1295–1297.
129. Martinez-Tello FJ, Tellez I. Extracardiac vascular and neural lesions in the toxic oil syndrome. J Am Coll Cardiol. 1991;18:1043–1047.
130. Gell P, Coombs R. Clinical Aspects of Immunology. 1st ed. Oxford: Blackwell; 1963.
131. Sell S. Immunopathology. In: Sell S, ed. Immunology, Immunopathology & Immunity. 6th ed. Washington, DC: ASM; 2003:235– 239.
132. Parish WE. Studies on vasculitis. I. Immunoglobulins, 1C, C-reactive protein, and bacterial antigens in cutaneous vasculitis lesions. Clin Allergy. 1971;1:97–109.
133. Parish WE. Microbial antigens in vasculitis. In: Wolff K, Winkelmann RK, eds. Vasculitis. London: Loyd-Luke Ltd; 1980:129–150.
134. Lerner L, Lio P, Flotte T. The prognostic significance of vascular immunoglobulin deposits in 94 cases of cutaneous leukocytoclastic vasculitis. J Cutan Pathol. 2000;27:562.
135. Ferri C, La Civita L, Longombardo G, et al. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus. 1998;7:275–279.
136. Crowson AN, Nuovo G, Ferri C, et al. The dermatopathologic manifestations of hepatitis C infection: a clinical, histological, and molecular assessment of 35 cases. Hum Pathol. 2003;34:573–579.
137. Weigand DA, Burgdorf WH, Tarpay MM. Vasculitis in cytomegalovirus infection. Arch Dermatol. 1980;116:1174–1176.
138. Walker DH, Occhino C, Tringali GR, et al. Pathogenesis of rickettsial eschars: the tache noire of boutonneuse fever. Hum Pathol. 1988;19: 1449–1454.
139. Dutz JP, Benoit L, Wang X, et al. Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood. 2001;97:95–100.
140. Uhoda I, Pierard-Franchimont C, Pierard GE. Varicella-zoster virus vasculitis: a case of recurrent varicella without epidermal involvement. Dermatology. 2000;200:173–175.
141. Shimizu J, Inatsu A, Oshima S, et al. Unique angiopathy after herpes virus infection. J Rheumatol. 2004;31:925–930.
142. Cohen P, Guillevin L. Vasculitis associated with viral infections. Presse Med. 2004;33:1371–1384.
143. Abril A, Calamia KT, Cohen MD. The Churg Strauss Syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum. 2003;33:106–114.
144. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998;7:238–258.
145. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol. 2001;14:1284–1293.
146. Chen KR, Su WPD, Pittelkow MR, et al. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol. 1996;35:173–182.
147. Chen KR, Pittelkow MR, Su D, et al. Recurrent cutaneous necrotizing eosinophilic vasculitis. A novel eosinophil-mediated syndrome. Arch Dermatol. 1994;130:1159–1166.
148. Mouthon L, Khaled M, Cohen P, et al. Systemic small sized vessel vasculitis after massive antigen inhalation. Ann Rheum Dis. 2001;60: 903–904.
149. Day CJ, Hewins P, Savage CO. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol. 2003;21(Suppl 32): S35–S48.
150. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–963.
151. Marinaki S, Neumann I, Kalsch AI, et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol. 2005;140:181–191.
152. Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Cleve Clin J Med. 2002;69
(Suppl 2):SII65–SII67.
153. Chanseaud Y, Pena-Lefebvre PG, Guilpain P, et al. IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple
endothelial cell antigens. Clin Immunol. 2003;109:165–178.
154. Arthus M. Injections repetees de serum de cheval chez le lapin. V R Soc Biol. 1903;55:817–820.
155. Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med. 1971;134:7s–8s.
156. Theofilopoulos AN, Dixon FJ. Immune complexes in human diseases: a review. Am J Pathol. 1980;100:529–594.
157. Gauthier VJ, Mannik M, Striker GE. Effect of cationized antibodies in performed immune complexes on deposition and persistence in renal glomeruli. J Exp Med. 1982;156:766–777.
158. Frank MM, Hamburger MI, Lawley TJ, et al. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med. 1979;300:518–523.
159. Clarkson SB, Kimberly RP, Valinsky JE, et al. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med. 1986;164:474–489.
160. Fernandez HN, Henson PM, Otani A, et al. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978;120:109–115.
161. Baumann U, Kohl J, Tschernig T, et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol. 2000;164: 1065–1070.
162. Hopken UE, Lu B, Gerard NP, et al. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med. 1997;186:749–756.
163. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 1994;265:1095–1098.
164. Baumann U, Chouchakova N, Gewecke B, et al. Distinct tissue sitespecific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung.
J Immunol. 2001;167:1022–1027.
165. Schiller C, Janssen-Graalfs I, Baumann U, et al. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol. 2000;30:481–490.
166. Kaburagi Y, Hasegawa M, Nagaoka T, et al. The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and L-selectin expression. J Immunol. 2002;168:2970–2978.
167. Zhang Y, Ramos BF, Jakschik BA. Augmentation of reverse arthus reaction by mast cells in mice. J Clin Invest. 1991;88:841–846.
168. Yanaba K, Kaburagi Y, Takehara K, et al. Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. Am J Pathol. 2003;162:1463–1473.
169. Yanaba K, Komura K, Horikawa M, et al. P-selectin glycoprotein ligand- 1 is required for the development of cutaneous vasculitis induced by immune complex deposition. J Leukoc Biol. 2004.

170. Burrows NP, Molina FA, Terenghi G, et al. Comparison of cell adhesion molecule expression in cutaneous leucocytoclastic and lymphocytic vasculitis. J Clin Pathol. 1994;47:939–944.
171. Sais G, Vidaller A, Jucgla A, et al. Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients. Arch Dermatol.
1997;133:443–450.
172. Bielsa I, Carrascosa JM, Hausmann G, et al. An immunohistopathologic study in cutaneous necrotizing vasculitis. J Cutan Pathol. 2000;27:130–135.
173. Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyteendothelial cell interactions. Arthritis Rheum. 2000;43:184–194.
174. Coll-Vinent B, Cebrian M, Cid MC, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum. 1998;41:435– 444.
175. Kano Y, Orihara M, Shiohara T. Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesions. Arch Dermatol. 1998;134: 62–67.
176. Sais G, Vidaller A. Pathogenesis of exercise-induced urticarial vasculitis lesions: can the changes be extrapolated to all leukocytoclastic vasculitis lesions? Arch Dermatol. 1999;135:87–89.
177. Cid MC. Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):SII45–SII49.
178. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with
corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43:294–301.
179. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447–452.
180. Boom BW, Mommaas M, Daha MR, et al. Complement-mediated endothelial cell damage in immune complex vasculitis of the skin: ultrastructural localization of the membrane attack complex. J Invest
Dermatol. 1989;93(Suppl 2):68S–72S

181. Braverman IM, Yen A. Demonstration of immune complexes in spontaneous and histamine-induced lesions and in normal skin of patients with leukocytoclastic angitis. J Invest Dermatol. 1975;64:105–112.
182. Sams WM Jr, Claman HN, Kohler PF, et al. Human necrotizing vasculitis: immunoglobulins and complement in vessel walls of cutaneous lesions and normal skin. J Invest Dermatol. 1975;64:441–445.
183. Tsai CC, Giangiacomo J, Zuckner J. Letter: Dermal IgA deposits in Henoch-Schonlein purpura and Berger’s nephritis. Lancet. 1975;1:342–343.
184. Van Hale HM, Gibson LE, Schroeter AL. Henoch-Schonlein vasculitis: direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol. 1986;15:665–670.
185. Gower R, Sams W, Thorne E, et al. Leukocytoclastic vasculitis: sequential appearence of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol. 1977;69:477–484.
186. Claudy A. Pathogenesis of leukocytoclastic vasculitis. Eur J Dermatol. 1998;8:75–79.
187. Sais G, Vidaller A, Peyri J. Anticardiolipin antibodies in leukocytoclastic vasculitis. J Am Acad Dermatol. 1997;37:805–806.
188. Kissel JT, Riethman JL, Omerza J, et al. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989;25: 291–297.
189. Kawana S, Shen GH, Kobayashi Y, et al. Membrane attack complex of complement in Henoch-Schonlein purpura skin and nephritis. Arch Dermatol Res. 1990;282:183–187.
190. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des. 2004;10:203–211.
191. Kawana S. The membrane attack complex of complement alters the membrane integrity of cultured endothelial cells: a possible pathophysiology for immune complex vasculitis. Acta Derm Venereol. 1996;76:
13–16.
192. Brack A, Geisler A, Martinez-Taboada VM, et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med. 1997;3:530–543.
193. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004;3:46–53.
194. Brogan PA, Shah V, Bagga A, et al. T cell Vbeta repertoires in childhood vasculitides. Clin Exp Immunol. 2003;131:517–527.
195. Popa ER, Stegeman CA, Bos NA, et al. Staphylococcal superantigens and T cell expansions in Wegener’s granulomatosis. Clin Exp Immunol. 2003;132:496–504.
196. Yarwood JM, Leung DY, Schlievert PM. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiol Lett. 2000;192:1–7.
197. Brogan PA, Shah V, Klein N, et al. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Arthritis Rheum. 2004;50:589–597.
198. Lopez-Hoyos M, Bartolome-Pacheco MJ, Blanco R, et al. Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis. 2004; 63:54–60.
199. Gupta-Malhotra M, Viteri-Jackson A, Thomas W, et al. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. Exp Mol Pathol. 2004;76:117–121.
200. Abe Y, Nakano S, Aita K, et al. Streptococcal and staphylococcal superantigen-induced lymphocytic arteritis in a local type experimental model: comparison with acute vasculitis in the Arthus reaction. J Lab
Clin Med. 1998;131:93–102.
201. Dvorak HF, Mihm MC Jr, Dvorak AM, et al. Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med. 1979;150:322–337.
202. Dvorak HF, Mihm MC Jr, Dvorak AM, et al. The microvasculature is the critical target of the immune response in vascularized skin allograft rejection. J Invest Dermatol. 1980;74:280–284.
203. Bhan AK, Mihm MC Jr, Dvorak HF. T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. J Immunol. 1982;129:1578–1583.
204. Dumler JS, Beschorner WE, Farmer ER, et al. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol. 1989;135:1097– 1103.
205. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359:2078–2083.
206. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217.
207. Kossard S. Defining lymphocytic vasculitis. Australas J Dermatol. 2000; 41:149–155.
208. Meehan SM, McCluskey RT, Pascual M, et al. Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1)
and cells with fragmented nuclear DNA. Lab Invest. 1997;76:639–649.
209. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723.
210. Libby P, Pober JS. Chronic rejection. Immunity. 2001;14:387–397.
211. Choy JC, Cruz RP, Kerjner A, et al. Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant. 2005;5:494–499.
212. Marks RM, Czerniecki M, Andrews BS, et al. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum. 1988;31: 1524–1534.
213. Kossard S, Spigel GT, Winkelmann RK. Cutaneous and subcutaneous endarteritis obliterans. Arch Dermatol. 1978;114:1652–1658.
214. Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjogren’s syndrome. Histologic classification and clinical presentation. Am J Clin Pathol. 1987;88:26–31.
215. Stephens CJ. Sneddon’s syndrome. Clin Exp Rheumatol. 1992;10:489– 492.
216. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300–309.
217. Lee T, Seo JW, Sumpio BE, et al. Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur J Vasc Endovasc Surg. 2003;25:451– 457.
218. Stone JH. Targeted therapies in systemic vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):SII124–SII128.
219. Langford CA, Sneller MC. Biologic therapies in the vasculitides. Curr Opin Rheumatol. 2003;15:3–10.

220. Salvarani C, Cantini F, Boiardi L, et al. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol. 2003; 21(Suppl 32):S23–S28.
221. Goronzy JJ, Weyand CM. Cytokines in giant-cell arteritis. Cleve Clin J Med. 2002;69(Suppl 2):SII91–SII94.
222. Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell arteritis. Cleve Clin J Med. 2002;69(Suppl 2):SII28–SII32.
223. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87:671–678.
224. Quinet RJ, Zakem JM, McCain M. Localized versus systemic vasculitis: diagnosis and management. Curr Rheumatol Rep. 2003;5:93–99.
225. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis. Serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol. 1990;126:69–72.
226. Wohlrab J, Fischer M, Wolter M, et al. Diagnostic impact and sensitivity of skin biopsies in Sneddon’s syndrome. A report of 15 cases. Br J Dermatol. 2001;145:285–288.
227. Marsch WC, Muckelmann R. Generalized racemose livedo with cerebrovascular lesions (Sneddon syndrome): an occlusive arteriolopathy due to proliferation and migration of medial smooth muscle cells. Br J
Dermatol. 1985;112:703–708.
228. Ha CT, Nousari HC. Surgical pearl: double-trephine punch biopsy technique for sampling subcutaneous tissue. J Am Acad Dermatol. 2003; 48:609–610.
229. LeBoit PE, Davis-Reed L. Light microscopy: clues to systemic disease in reexcision specimens of basal cell carcinoma. Am J Dermatopathol. 1999;21:361–364.
230. Hamidou MA, Moreau A, Toquet C, et al. Temporal arteritis associatedwith systemic necrotizing vasculitis. J Rheumatol. 2003;30:2165–2169.
231. Genereau T, Lortholary O, Pottier MA, et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum. 1999;42:2674–2681.
232. Nieboer C. Immunofluorescence patterns in sun-exposed and not-sunexposed skin of healthy individuals. Acta Derm Venereol. 1981;61:471–479.
233. Davis MD, Daoud MS, Kirby B, et al. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998;38:899–905.
234. Brogan PA, Shah V, Brachet C, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50:927–936.
235. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol. 2004;16:18–24.
236. Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost. 1996;75:892–898.
237. Preston GA, Yang JJ, Xiao H, et al. Understanding the pathogenesis of ANCA: where are we today? Cleve Clin J Med. 2002;69(Suppl 2):SII51– SII54.
238. Specks U. ANCA subsets: influence on disease phenotype. Cleve Clin J Med. 2002;69(Suppl 2):SII56–SII59.
239. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford). 2002;41:481–483.
240. Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev. 2003;2:158–164.
241. Vena GA, Cassano N. Immunosuppressive therapy in cutaneous vasculitis. Clin Dermatol. 1999;17:633–640.
242. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum. 2003;49:151–155.
243. Hermann J, Demel U, Stunzner D, et al. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis. 2005;64:641–643.
244. McLaren JS, Stimson RH, McRorie ER, et al. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM. 2001;94:615–621.
245. Ayoub N, Charuel JL, Diemert MC, et al. Antineutrophil cytoplasmic antibodies of IgA class in neutrophilic dermatoses with emphasis on erythema elevatum diutinum. Arch Dermatol. 2004;140:931–936.
246. Rovel-Guitera P, Diemert MC, Charuel JL, et al. IgA antineutrophil cytoplasmic antibodies in cutaneous vasculitis. Br J Dermatol. 2000; 143:99–103.
247. Burke AP, Virmani R. Localized vasculitis. Semin Diagn Pathol. 2001; 18:59–66.
248. Chen KR. Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases. J Dermatol. 1989;16:429–442.
249. Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD, et al. Schonlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol.
1997;133:438–442.
250. Rieu P, Noel LH. Henoch-Schonlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris). 1999;150:151–159.
251. Kawasaki Y, Suzuki J, Sakai N, et al. Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis. Clin Nephrol. 2003;60:153–160.
252. Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, et al. Hypersensitivity vasculitis in adults: a benign disease usually limited to skin. Clin Exp Rheumatol. 2001;19:85–88.
253. Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation. 2000;102:1470–1472.
254. Willcocks L, Chelliah G, Brown R, et al. Cutaneous vasculitis—a case for laparotomy? J Rheumatol. 2003;30:1621–1623.
255. Koss T, Carter EL, Grossman ME, et al. Increased detection of rickettsialpox in a New York City hospital following the anthrax outbreak of 2001: use of immunohistochemistry for the rapid confirmation
of cases in an era of bioterrorism. Arch Dermatol. 2003;139:1545–1552.
256. Dumler JS, Gage WR, Pettis GL, et al. Rapid immunoperoxidase demonstration of Rickettsia rickettsii in fixed cutaneous specimens from patients with Rocky Mountain spotted fever. Am J Clin Pathol. 1990;93:
410–414.
257. Kao GF, Evancho CD, Ioffe O, et al. Cutaneous histopathology of Rocky Mountain spotted fever. J Cutan Pathol. 1997;24:604–610.
258. Grau GE, Roux-Lombard P, Gysler C, et al. Serum cytokine changes in systemic vasculitis. Immunology. 1989;68:196–198.
259. Spry CJ, Tai PC, Barkans J. Tissue localization of human eosinophil cationic proteins in allergic diseases. Int Arch Allergy Appl Immunol. 1985;77:252–254.
260. Davis MD, Daoud MS, McEvoy MT, et al. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997;37:199–203.
261. Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994;31:605–612.
262. Bajema IM, Hagen EC, van der Woude FJ, et al. Wegener’s granulomatosis: a meta-analysis of 349 literary case reports. J Lab Clin Med. 1997;129:17–22.
263. Kuchel J, Lee S. Cutaneous Wegener’s granulomatosis: a variant or atypical localized form? Australas J Dermatol. 2003;44:129–135.
264. Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol. 2001;18:3–13.
265. Viac J, Pernet I, Schmitt D, et al. Overexpression of circulating vascular endothelial growth factor (VEGF) in leukocytoclastic vasculitis. Arch Dermatol Res. 1999;291:622–623.
266. Ferri C, Giuggioli D, Cazzato M, et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol. 2003;21(Suppl 32):S78–S84.
267. Coll-Vinent B, Grau JM, Lopez-Soto A, et al. Circulating soluble adhesion molecules in patients with classical polyarteritis nodosa. Br J Rheumatol. 1997;36:1178–1183.
268. Frances C, Le Tonqueze M, Salohzin KV, et al. Prevalence of antiendothelial cell antibodies in patients with Sneddon’s syndrome. J Am Acad Dermatol. 1995;33:64–68.
269. Sepp N, Zelger B, Schuler G, et al. Sneddon’s syndrome–an inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence. Am J
Surg Pathol. 1995;19:448–453.
270. Schmitt WH, Gross WL. Vasculitis in the seriously ill patient: diagnostic approaches and therapeutic options in ANCA-associated vasculitis. Kidney Int Suppl. 1998;64:S39–S44.
271. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337: 1512–1523

Review article text

Tables

Figures 1

Figures 2